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Abstract: Here we describe the development of an improved workflow for utilizing 
experimental and simulated protein conformations in the structure-based design of inhibitors 
for anti-apoptotic Bcl-2 family proteins. Traditional structure-based approaches on similar 
targets are often constrained by the sparsity of available structures and difficulties in finding 
lead compounds that dock against flat, flexible protein-protein interaction surfaces. By 
employing computational docking of known small molecule inhibitors, we have demonstrated 
that structural ensembles derived from either accelerated MD (aMD) or MD in the presence 
of an organic cosolvent generally give better scores than those assessed from analogous 
conventional MD. Furthermore, conformations obtained from combined cosolvent aMD 
simulations started with the apo-Bcl-xL structure yielded better average and minimum docking 
scores for known binders than an ensemble of 72 experimental apo- and ligand-bound Bcl-xL 
structures. A detailed analysis of the simulated conformations indicates that the aMD 
effectively enhanced conformational sampling of the flexible helices flanking the main Bcl-xL 
binding groove, permitting the cosolvent acting as small ligands to penetrate more deeply 
into the binding pocket and shape ligand-bound conformations not evident in conventional 
simulations. We believe this approach could be useful for identifying inhibitors against other 
protein-protein interaction systems involving highly flexible binding sites, particularly for 
targets with less accumulated structural data. 
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1. Introduction 
The Bcl-2 protein family constitutes a central class of regulators for the intrinsic apoptotic pathway [1]. 
The balance between pro- and anti-apoptotic members from this family is the major factor affecting 
mitochondrial outer membrane permeability, which induces cytochrome c release and leads to activation 
of downstream caspases [1]. Specific control of caspase activity in the cell by Bcl-2 family proteins is 
also required for differentiation and hematopoietic tissue homeostasis [2–4]. In many diseases, the 
apoptotic machinery in cells is dysfunctional and apoptosis becomes misregulated [5]. In cancer cells, 
overexpression of anti-apoptotic members can serve as a driving force for tumorigenesis or for acquisition 
of chemoresistance against drug treatments [6,7]. One widely pursued approach in apoptosis-based 
therapy entails developing chemical agents to inhibit the anti-apoptotic members of Bcl-2 proteins [5,8–11]. 
ABT-263 [12–14] and ABT-199 [15] are two potent inhibitors that have been successfully designed to 
target a subset of the anti-apoptotic Bcl-2 proteins, e.g. Bcl-xL, Bcl-2, and Bcl-w [16]. These two 
compounds are currently in late-stage clinical trials for treating myeloma, lymphoma, leukemia, and 
certain lung cancers [14,17]. 
Developing small molecules to inhibit the function of the anti-apoptotic members of the Bcl-2 proteins 
is challenging because it involves the inhibition of protein–protein interactions [18–21]. Anti-apoptotic 
Bcl-2 proteins have a long and flexible hydrophobic binding groove, which serves as a docking site for BH3 
(Bcl-2 homology 3) domain-only proteins [22]. This protein–protein interaction prevents the latter from 
carrying out pro-apoptotic activities that would otherwise promote cell death [23]. Available crystal 
structures have revealed that the interaction between anti-apoptotic and pro-apoptotic members of the 
Bcl-2 proteins is mediated via four hydrophobic residues and one acidic residue of the pro-apoptotic 
members [24,25]. Using a “SAR-by-NMR” approach—followed by medicinal chemistry optimization 
targeting the anti-apoptotic Bcl-xL and Bcl-2 proteins—ABT-737 and ABT-199 were both developed from 
the same core scaffold [16]. Although many small molecule inhibitors have been reported to date [10,26,27], 
compounds with similar or higher potencies than ABT-737 and ABT-199 contain similar core structures and 
are all in early preclinical studies (e.g. TM-957 [28] and compounds based on quinazoline sulfonamides [29]). 
Furthermore, these compounds have very high binding affinities to Bcl-2, Bcl-xL, and Bcl-w, but not to 
other anti-apoptotic members such as Bcl2A1, Mcl-1, and Bcl-B. For example, ABT-737 binds to Bcl-2, 
Bcl-xL, and Bcl-w with a Ki of <1 nM, but has > 1000× weaker affinity to Mcl-1 and Bcl2A1 [16]. Because 
tumor cells can become resistant to ABT-737 or ABT-199 upon treatment by upregulating Mcl-1 and 
Bcl2A1 [30–32], next-generation small molecule inhibitors that target selectively Bcl2A1, Mcl-1 [33], and 
Bcl-B—or act as pan-Bcl-2 family inhibitors [34,35]—are highly desirable for future apoptosis-based 
cancer therapeutics [27]. 
Because the BH3-domain binding groove of anti-apoptotic Bcl-2 proteins is long and flexible, it can 
adopt multiple conformations and should in theory be able to bind ligands with substantially different 
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physical topologies [22,36]. As mentioned before, however, there are currently only a handful of 
different scaffolds that have been developed into lead compounds with sufficient in vivo efficacy. This 
can be partly attributed to the limited degree of compound diversity in the small-molecule co-crystal 
structures that are available to use as the starting point for rational, structure-based drug design efforts. 
Additionally, no small-molecule co-crystal structures for Bcl2A1, Bcl-b, and Bcl-w have been reported 
to date. Despite their limitations, the co-crystal structures that are currently available can still be used as 
starting points for computational simulations that can potentially provide a much needed enrichment of 
conformations of the protein–protein interaction site. 
Rational structure-based drug design efforts that aim to inhibit protein–protein interactions typically 
start with knowledge of a protein-protein or protein-peptide complex structure. The binding sites in these 
structures often conform to accommodate their relatively large binding partner. This results in non-optimal 
pocket conformations for small molecule binding, raising the question of whether these sites are 
druggable by small molecules. In such cases, the native ligand in the structure may be removed and 
molecular dynamics used to facilitate the sampling of conformations that are potentially more compatible 
to small molecule binding. However, this approach can limit the generation of larger exposed 
hydrophobic pockets due to unfavorable protein hydration. To assess druggability for PPI targets, a 
recent report proposed to carry out MD simulations with soluble organic cosolvent molecules [37]. In 
such simulations, the cosolvent molecules probe the interaction site and also help to reveal how the protein 
can be expected to respond when a generic small molecule ligand enters the binding site. Besides probing 
the binding site, the inclusion of cosolvent molecules in the system can also alter the population of protein 
conformations at equilibrium [38,39] and influence the dynamic transition rate of xylanase[40]. By 
employing these computational strategies, we have compared MD simulations starting from apo Bcl-xL 
in either a pure water or cosolvent environment and observed that the cosolvent simulations produced 
conformations with structural characteristics specific to known co-complex structures, while the pure 
water simulations did not [41]. One inherent challenge to our previous study is that the system may 
become trapped in energy minima, resulting in restricted conformational sampling across timescales 
common in conventional MD simulations. Accelerated molecular dynamics (aMD) offers a potential 
solution to this problem in that it utilizes a “boost potential” to essentially raise the energy wells and 
allow the system to overcome kinetic barriers more easily [42]. Compared to analogous conventional 
MD simulations, aMD has been shown to sample a larger range of protein conformational space, 
including an enhanced degree of sampling of small molecule binding hotspots [43]. 
In this work, we combined the aMD and cosolvent MD simulation methods to achieve efficient 
sampling from an apo-form protein in the presence of small cosolvent molecules acting as ligands. The  
anti-apoptotic Bcl-2 family member Bcl-xL was used as a test system because there is a relative 
abundance of small molecule co-complex structures available for Bcl-xL compared to other Bcl-2 family 
members. Conformations of one apo-form and one Bad BH3 peptide-bound Bcl-xL structure obtained 
from simulations using (a) pure water conventional MD, (b) cosolvent MD (with an isopropanol probe), 
(c) accelerated MD, (d) and cosolvent aMD were compared to the crystal structure conformations 
through principal component analysis (PCA). To assess the relative similarity between structures within 
a given simulation setting, we clustered the conformations from each trajectory in the subspace derived 
from the first and second principal components of the crystal structure PCA. Representative conformations 
were selected for a follow-up virtual screening evaluation—using 27 known small molecule inhibitors 
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without reported co-crystal structures and 147 decoy compounds—to assess the small-molecule ligand 
binding capacity of our simulated conformations. Our results showed that the conformations of apo-form 
Bcl-xL in a cosolvent environment with accelerated MD yielded the greatest overall conformational 
variation in the experimental structure PC subspace. Structures obtained from this simulation setting also 
generally yielded more favorable docking scores for our entire set of small molecule compounds, 
suggesting that their associated binding site conformations are more adaptive to a wide range of small 
molecule ligands in virtual screening calculations. Taken together, the combination of aMD and cosolvent 
MD is an attractive approach for generating and enriching protein binding site conformations complementary 
to small molecule ligands, and can be useful for virtual screening studies aiming to identify novel ligands 
for subsequent biological evaluation. We believe this method should be particularly useful when only 
the apo-form crystal structure of a target protein is available, assuming the MD force field parameters 
can produce accurate conformational sampling. Our study suggests that the implementation of this 
approach would be helpful in identifying novel chemical leads to jump-start a small-molecule drug 
discovery program for other pro-apoptotic Bcl-2 family members such as Bcl2A1 or Bcl-w. 
2. Experimental Section 
All experimental and simulated structural data were analyzed with the Bio3D package [44]. The 
sequence of the crystallographic structure for human apo Bcl-xL (PDB code: 1MAZ) was used to 
BLAST [45] search the RCSB PDB for homologous structures. A total of 221 hits for the Bcl-2 family 
were reported, from which a sequence identity cutoff of 70% was used to isolate only Bcl-xL structures. 
This yielded a set of 56 unique PDB structures encompassing a total of 80 different chains. These 
structures include wild-type and mutant Bcl-xL from human, mouse, and rat. All are modified constructs 
with the membrane-binding C-terminal domain removed. Wild-type Bcl-xL protein contains a 60-residue 
loop between α1 and α2 that is absent in the majority of structures (a notable exception is PDB code: 
1LXL, a solution NMR structure). It has been demonstrated in previous experiments that this loop is not 
required for anti-apoptotic activity [46]. 
The amino acid sequences of the 82 different chains were aligned using the MUSCLE algorithm [47]. 
Two of the chains (PDB code: 3IO8 chain A and 4HNJ chain B) were found to have significant gaps in 
key α3 residues, and hence these structures were omitted from subsequent analysis. All conformations were 
then structurally superimposed upon each other via least-squares-fitting of the Cartesian coordinates of 
equivalent C-α atoms from α2 and α5—as these two helices were found to be the most structurally 
invariant regions with respect to the BH3-domain binding groove. Three distinct folding patterns were 
identified in the overall set; 41 are globular monomers, 14 engage in α1 domain swapping, and two 
engage in α6/α8 domain swapping. 
Principal component analysis (PCA) was used to assess inter-conformer relationships in the set of 
superimposed structures. This technique has previously been shown to be a valuable tool for assessing 
experimental structure distributions and comparing them to conformations obtained through MD 
simulations. In mathematical terms, PCA involves building and then diagonalizing a covariance matrix C, 
having elements Cij, from the Cartesian coordinates r of equivalent atoms from the superimposed 
experimental structures: 
??? ? ???? ? ????? ? ??? ? ?????? (1) 
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For N number of atoms, i and j are all the possible pairs of 3N Cartesian coordinates. The eigenvalues 
for the covariance matrix give the variance of the overall distribution along their respective eigenvectors, 
which themselves correspond to a linearized basis of the structural distribution and are also referred to 
as the “principal components” [48]. 
Both the experimental structures and MD trajectory frames were mapped into a subspace built from 
the dominant PCs to provide a lower dimensional representation of the original data. In this case, PCA 
was carried out on the Cartesian coordinates of C-α atoms from the region comprised of α2, α3, α4, α5, 
and all intervening loops. This roughly defines the region circumscribing the BH3-domain binding 
groove. It should be noted that α7 could also have been included here; however, the helix engages in 
domain-swapping in several structures from the experimental set. Since this study is primarily focused 
on the protein’s monomeric behavior, the helix was excluded from the PCA. 
Regional flexibility in the set of experimental structures was compared to that seen in the MD 
trajectories by calculating residue-wise root-mean-squared fluctuations (RMSFs) for all C-α atoms. We 
also measured root-mean-squared deviation (RMSD) values for C-α atoms from individual helices in 
order to assess transitions between distinct structural states in the MD trajectories. 
A series of conventional and accelerated molecular dynamics (MD) simulations were run using the 
Bad-bound (PDB code: 2BZW) and apo (PDB code: 1MAZ) crystal structures as starting conformations. 
The aMD method works to enhance conformational sampling by implementing a “boost” potential ΔV 
if the value of the potential energy is below a pre-specified threshold Eb:  
????? ? ????? ???? ? ?? (2) 
????? ? ???? ? ?????? ???? ? ?? (3) 
and 
????? ?
??? ????????
?
?? ??????? ?? 
(4) 
Here, the aMD threshold potential and acceleration parameter (α) were determined via the method 
used by Grant et al. [49]. 
All simulations were carried out using the CUDA implementation of the AMBER PMEMD  
method [50], with each individual simulation being run on a single NVIDIA GeForce GTX 680 GPU 
from the high-performance computing cluster at the University of Michigan Center for Computational 
Medicine & Bioinformatics. Simulations were run in either pure aqueous or 20% v/v isopropanol cosolvent 
solutions. Protonation states for ionizable groups were determined via the PROPKA method [51], and 
negative charges were neutralized using Na+ counter ions. For simulations carried out in pure water, the 
prepared protein structure was placed in a 13-Å octahedral water box using the TIP3P water model [52]. 
Cosolvent simulations entailed the use of a 13-Å octahedral cosolvent box of 20% v/v isopropanol in 
water, designed and supplied by Xavier Barril [37]. 
Minimization was carried out through 1000 steps of the conjugated gradient method followed by 2000 
steps of steepest descent. The temperature of the system was raised from 0 to 298 K via 50 ps of simulation 
with constant volume/constant temperature in the canonical ensemble (NVT), with a 5 kcal/mol/Å2 force 
constraint on all backbone atoms. This was followed by 200 ps of simulation with constant pressure/constant 
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temperature in the isothermal-isobaric ensemble (NPT), with a 2 kcal/mol/Å2 force constraint. Finally, 
100 ns of production aMD were run under NPT conditions at 298K and 1 atm, with 2 fs time-steps. The 
SHAKE algorithm [53] was used to keep all hydrogen bonds fixed, and the cutoff for non-bonded 
interactions was set to 12 Å. Protocols for minimization and equilibration of the Bcl-xL cosolvent system 
were the same as those utilized by Yang and Wang [54]. 
We note that even with the relatively high van der Waal’s cutoff, as well as the additional calculations 
required for aMD, each 100 ns simulation of the 139 residue long Bcl-xL protein finished in approximately 
four days. This represents nearly a 19-fold increase in runtime efficiency over similar simulations run 
previously [41,54], which we attribute to using the CUDA implementation of PMEMD to carry out our 
simulations on NVIDIA GPUs. 
Our grid-based hotspot mapping method was implemented as follows: the crystal structure of  
Bcl-xL/ABT-737 was aligned to the first conformation from the trajectories to extract ABT-737 as the 
reference ligand at the binding site. A 1-Å uniformly spaced grid was then set up with the origin at the 
center of mass of ABT-737. Grid points within 1.5 Å of the van der Waals’ radius of the protein atoms 
were removed. The remaining grid points within 3 Å of ABT-737 were considered to be within the 
binding site and saved for subsequent calculations. For the saved grid points, the “buriedness” of each 
grid point was calculated using a ray tracing method similar to Sitemap [55]. Specifically, 12 rays were 
emanated from each grid point, checking for any neighboring protein atoms in the binding site. If 10 of 
the 12 rays at a given grid point crossed any protein atom in the binding site, and the point was surrounded 
by more than three neighboring points with the same property, the grid point was considered “buried.” 
The latter of these two criteria allows for elimination of the boundary layer of grid points that are also 
highly exposed. The buried grid points were then saved, assigned the C.3 atom type, and evaluated for 
their interactions with the protein via M-Score [56]. After all the buried grid points were assigned scores, 
those grid points with scores better than one quarter of the lowest score were collected. If a grid point in 
this collection was also surrounded by more than four such grid points, it was designated as a “hotspot” 
grid point. When evaluating the hotspot grid points in an ensemble of conformations, all Bcl-xL 
conformations were aligned to the α5 helix of the apo-Bcl-xL crystal structure (PDB ID: 1MAZ), again 
using the center of mass of ABT-737 as the grid origin. By this setup, the same Cartesian coordinate system 
was used throughout the entire ensemble of Bcl-xL conformations in our evaluation. 
3. Results and Discussion 
3.1. Mapping of Bcl-xL Experimental Conformations Reveals Distinct Apo and a Diversity of Peptide 
and Inhibitor-Bound Forms  
Principal component analysis was used to evaluate structural variation in the vicinity of the BH3 
binding groove for all available Bcl-xL experimental structures (Figure 1; see Experimental Section for 
details). The first PC accounts for 51.5% of the total variance and corresponds to a coupled translational 
motion in the region comprised of α3, α4, and the α3–α4 loop. Our definition of alpha helix numbers 
follows previous reports [41]. In structures with more positive scores along PC1, the region is shifted 
upward, whereas in structures with more negative PC1 scores it is shifted downward. An additional 
16.7% of the variance is captured by the second PC, for which positive and negative scores correspond 
to leftward and rightward longitudinal shifts in α3, respectively. 
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Figure 1. The PC subspace for the BH3-domain binding pocket of Bcl-xL experimental 
structures contains three general conformational groupings. The group furthest to the  
right (yellow circle) is dominated by peptide-bound conformations, in which α3 and α4 are 
shifted downward with respect to the apo structures (green circle). Meanwhile, the  
benzathiazole-hydrazone and acyl-sulfonamide inhibitor-bound structures (red circle) have  
an upward shifted α3 and α4 and a rightward shifted α3 with respect to the  
peptide-bound structures. 
Nearly all of the known apo structures form a distinct structural subgroup that is clearly separated 
from the peptide-bound and inhibitor-bound structures (Figure 1, green points). A notable outlier is 
2B48—an α6-α8 domain swapped dimer. Apart from this exception, the conformation of the BH3-domain 
binding groove region is nearly identical across the entire apo subgroup. Specifically, in contrast to other 
structures, α4 is bent upward, which facilitates a corresponding upward shift in α3 and allows the phenyl 
moiety from Phe105 to occupy the p2 pocket. 
The holo (or non-apo) structures are distributed across a wider range of overlapping conformational 
space (Figure 1, yellow and red points). This reflects the significant diversity of peptides and ligands 
that are capable of docking in the BH3-domain binding groove. For the majority of these structures, α3 
and α4 are shifted downward with respect to the apo structure, providing access to the hydrophobic 
pockets that mediate the interaction between protein and peptide or protein and ligand. PC1 and PC2 divide 
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the holo set into two subgroups. The larger group contains most of the peptide-bound structures and a 
handful of ligand-bound co-complexes, including that for the well-known inhibitor ABT-737 (PDB code: 
2YXJ). Structures from this group generally have more positive PC1 and PC2 values, representing 
conformations in which α3 and α4 are shifted downward and α3 is shifted leftward. The smaller group 
is comprised primarily of co-complexes associated with a special class of compounds containing a 
benzathiazole moiety, which binds in the p2 pocket of the BH3-domain binding groove. As a whole, the 
group is generally characterized by more negative values for both PCs, corresponding to conformations 
in which α3 and α4 are shifted upward while α3 is shifted longitudinally rightward. 
Because the first two PCs account for a substantial majority of the conformational variation, we clustered 
the experimental structures in the PC1-PC2 subspace, allowing us to divide the set into 12 distinguishable 
subgroups. Roughly speaking, the benzathiazole-containing co-complexes comprise two of these clusters, 
and the rest of the ligand and peptide-bound structures are spread across another eight clusters. All but 
two of the apo structures fall into a single cluster. One of the outliers is the aforementioned domain-swapped 
dimer 2B48, while the other is the solution NMR structure 1LXL (which contains the full sequence of 
the Bcl-xL protein). The procedure for clustering the experimental structures was used to establish a 
similar protocol for clustering simulated conformations (see Experimental Section for details). 
3.2. Conventional MD Captures Relaxation from Peptide-Bound to Apo-Like Conformations 
Previously, Yang and Wang reported that a 50 ns simulation of holo-Bcl-xL/Bad (commencing from 
PDB code: 2BZW) in pure water did not sample the apo structure conformational space at any point [54]. 
For this study, we extended the simulation for another 50 ns in order to observe whether a longer timeframe 
would allow the protein to escape the holo-structure conformational space. Interestingly, the simulation 
yielded a relaxation to an apo-like state within the extended time period. An assessment of the time 
evolution of RMSD values to the canonical apo crystal structure (PDB code: 1MAZ) revealed that the 
transition occurred via three sequential steps (Figure 2D–F); first, α3 elongates, gaining one helical turn 
at its N-terminal end. This is reflected in a net RMSD decrease from approximately 5 Å to 4 Å over the 
first 30 ns. Next, α4 shifts sharply upward between 66 and 69 ns—yielding a decrease in RMSD from 
~5 Å to 1 Å. The helix continues fluctuating upward and downward throughout the next 20 ns, with 
RMSD values varying from ~1–3 Å. Finally, α3 and α4 engage in a coupled upward shift at 86 ns, with 
the final α3 and α4 RMSDs dropping to ~2.7 Å and ~1.3 Å, respectively. The positions of α1, α2, and 
α5–α7 are relatively consistent between apo- and holo- Bcl-xL crystal structures, and the trajectory 
revealed only minor flexibility in these regions (Figure 2, Table S1). It should be noted that despite the 
dramatic decrease in α3 and α4 RMSD with respect to the 1MAZ PDB structure, the simulation did not 
fully reach the native apo conformation. In particular, the conformation of the α3–α4 loop in the final 14 ns 
of the trajectory differs substantially from the canonical apo structure, with an RMSD of over 6 Å. 
The results of projecting the trajectory frames into the experimental structure PC1-PC2 subspace 
corroborated the conclusions drawn from the RMSD analysis (Figure 2B). As mentioned previously, 
PC1 represents an upward shift in α3 and α4. Because the initial refolding of α3 draws the overall α3 
backbone slightly upward, most of the frames from the first 69 ns of the trajectory have slightly more 
negative PC1 scores than the starting structure. On a similar note, the sharp upward movement of α4 
between 66 and 69 ns brings the trajectory frames even closer to the experimental apo structures along 
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PC1. At 86 ns, the final coupled upward shift of α3 and α4 puts the trajectory frames just to the upper 
left of the apo set. Our observation that the trajectory did not fully reach the true native apo conformation 
is reflected here in the fact that the trajectory frames from the last 14 ns do not directly overlap with the 
apo crystal structures. 
 
Figure 2. (A) RMSDs of α2, α3, α4, α5, α7, and the full-length protein for a 100 ns 
simulation starting from the Bad-bound structure (red) and the apo structure (black). The 
former saw a relaxation to an apo-like state after 86 ns, with key transition points indicated by 
vertical blue lines. (B) Specific portions of the trajectory corresponding to different time 
intervals were projected into the experimental structure PC subspace (blue points) for 
comparison to the RMSD analysis. (C) Crystal structures of apo- and Bad-bound Bcl-xL were 
aligned to depict the end states. Corresponding conformations at (D) 0 ns, (E) 69 ns, and  
(F) 90 ns are shown. For (C–F), the reference apo Bcl-xL structure is colored in orange. For 
the aligned conformations, the purple and green segments denote α3 and α4 helices along with 
other Bcl-xL segments colored grey. 
A 50 ns simulation of the Bcl-xL apo structure (PDB code: 1MAZ), also carried out by Yang and 
Wang [54], was reported to yield only minor deviations from the original crystal structure. As in the 
investigation of the holo-structure, we extended the apo simulation for another 50 nanoseconds. In this 
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case, the extended portion resembled the initial 50 nanoseconds of the trajectory. Significant motions were 
restricted to α3 (Figure 2) and the α2–α3 loop (first half RMSD range: ~1–5 Å; second half RMSD range: 
~1–4 Å). The simulation’s projection in the experimental structure PC subspace is consistent with these 
observations, with the trajectory frames being restricted to a small area centered on the apo crystal 
structures (Figure 3A). 
 
Figure 3. Projection of Bcl-xL conformations into the experimental structure PC1-PC2 
subspace, from MD simulations using conventional MD (cMD) in water or a 20% v/v 
isopropanol/water cosolvent environment, along with accelerated MD (aMD) using low or 
high acceleration parameters. Simulations started with (A–C) apo-Bcl-xl (PDB code: 1MAZ) in 
water, with (D–F) Bad-bound Bcl-xL (PDB code: 2BZW) in water, and with (G–I) apo-Bcl-xl 
(PDB code: 1MAZ) in cosolvent environment. All simulations were run for 100 ns except 
for the 1MAZ cMD in cosolvent, which was run for 33 ns. 
3.3. Simulations with Enhanced Sampling Reveal Distinctive Conformational Landscapes 
In order to further explore the dynamical characteristics of the Bcl-xL protein, we implemented 
several different techniques for enhancing conformational sampling on the apo- and holo-Bcl-xL crystal 
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structures. First, we carried out two separate accelerated molecular dynamics (aMD) simulations on 
holo-Bcl-xL in a pure water environment, utilizing several different values for the aMD acceleration 
parameters. RMSD analysis and projection of the simulation snapshots into the crystal structure PC 
subspace revealed that both the “low boost” and “high boost” trajectories were able to generate extensive 
conformational sampling, although neither was able to sample the apo structure conformational space 
(Figure 3E–F). The high boost simulation exhibited the largest overall backbone motions (avg. RMSD: 
4.71 ± 0.95), while the low boost simulation generated the largest fluctuations for α3 (avg. RMSD:  
5.51 ± 2.44 Å). In the experimental structure PC subspace, the two trajectories had a similar degree of 
conformational sampling along PC1, whereas sampling along PC2 was greater for the low boost 
simulation (Figure 3E–F). Interestingly, in both trajectories, Phe105 becomes incorporated into α2 instead 
of into α3 as in the cMD simulation. Moreover, α2 and α3 end up combining into a single extended helix, 
though the effect is quite transient in the low boost simulation. 
Simulations of apo-Bcl-xL in pure water using aMD also exhibited a fairly high degree of conformational 
variation, with the largest motions occurring in α3 for the low boost simulation (avg. RMSD: 3.89 ± 1.06 Å) 
and in α3 and α7 for the high boost simulation (avg. RMSDs: 3.13 ± 0.87 Å and 4.21 ± 1.44 Å). The trajectory 
projections cover a wider area in the experimental structure PC subspace than the apo cMD simulation, 
though the amount of overlap with the ligand and peptide-bound structures is limited (Figure 3B,C). 
It has been noted previously that Bcl-xL simulations carried out in a cosolvent environment can 
enhance the protein’s conformational sampling. In particular, Yang and Wang [41] found that cosolvent 
simulations of apo- and holo-Bcl-xL were capable of generating conformations of the BH3-domain 
binding site that were not seen in analogous pure water simulations and exhibited features reminiscent 
of other cocrystal structures for Bcl-xL. However, the trajectory projection of the apo structure cosolvent 
simulation demonstrates that, like the cMD and aMD simulations in water, the extent of conformational 
sampling was limited to the area around the apo crystal structures (Figure 3G). We subsequently 
combined the aMD and cosolvent simulation methods in an attempt to facilitate wider conformational 
sampling of the apo structure. We found that the implementation of these enhanced sampling techniques 
in tandem can generate much greater motions than either one used separately, as the average backbone 
RMSD was far greater in the two cosolvent aMD simulations (5.61 ± 1.84 Å for low boost, 5.10 ± 1.86 Å 
for high boost) than any other simulation from the apo structure. Motions in α3 (5.61 ± 1.84 Å for low 
boost, 5.10 ± 1.86 Å for high boost) and α4 (5.61 ± 1.84 Å for low boost, 5.10 ± 1.86 Å for high boost) 
were particularly high, and the projection of the trajectories into the experimental structure PC subspace 
clearly demonstrates that the simulations were able to sample areas far beyond the apo crystal structures 
(Figure 3H–I). 
In summary, the PCA results indicate that the simulations with enhanced sampling covered a large 
conformational space corresponding to a wide array of cocrystal forms. In the case of the apo structure, 
the combination of aMD and a cosolvent environment allowed the protein to achieve much wider 
sampling than using either method separately. This feature could be particularly helpful for systems 
where there may be a limited number of co-crystal structures available. We conclude that enhanced 
sampling MD simulations can be used to sample distinct structural landscapes that may not be readily 
accessible by traditional simulation methods, which may in turn facilitate the design of inhibitors for 
flexible protein targets with limited available experimental structure data. 
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3.4. Structural Ensemble Generation and Small Molecule Docking 
Our next objective was to assess whether any of the conformations generated from the apo structure 
simulations were amenable to in silico docking against small molecule inhibitors. To achieve this, we 
compared docking scores for a set of known Bcl-xL inhibitors against five structural ensembles: one 
comprised of 72 experimentally determined Bcl-xL conformations, and the other four made up of 
trajectory conformations taken from each of the previously discussed apo-Bcl-xL simulations. To 
generate structural ensembles of a manageable size for small molecule docking, we first carried out 
hierarchical clustering on the full set of frames from each trajectory using the same protocols as for the 
crystal structure clustering. This yielded a total of nine clusters for the pure water cMD simulation, seven 
clusters for the cosolvent cMD simulation, 11 clusters for the pure water aMD simulation, and 64 clusters 
for the cosolvent aMD simulation. We then selected a single structural representative from each cluster 
by identifying their centroids, i.e. the conformations with the lowest RMSD to the average conformation 
of each respective cluster. 
In order to achieve an unbiased comparison, we focused primarily on Bcl-xL inhibitors that do not 
have co-complex structures reported in the PDB. In the end, we selected a set of 27 natural and synthetic 
compounds of various sizes and chemical classifications (Figure 4), all of which have been reported to 
have inhibitory activity against Bcl-xL. Binding between Bcl-xL and the IK compound series was 
confirmed via 1D and 2D NMR spectroscopy [57–59]. PJH_1 is a fragment derived from ABT-737 and 
has a pKD value of 3.5 [60]. Kendomycin [61], Chelerythrine [62], YC137 [63], BH3I_1a, BH3I_1b, 
BH3I_2 [64,65], and gossypol [66] were discovered by various research groups and their binding 
affinities to Bcl-xL have been confirmed by numerous reports including a recent study by Wan et al. [67]. 
Lessene_hit6 is a compound discovered by Lessene and coworkers [68] from a high-throughput screen and 
has a different scaffold from all other confirmed inhibitors. We note that several co-crystal structures 
with Bcl-xL have been determined for various derivatives of the original HTS hit (PDB codes: 3ZK6, 
3ZLN, 3ZLO, 3ZLR). Repeated confirmed binding and structural data of these 27 compounds by 
different groups gives us confidence that their binding activity is not the result of assay artifacts. 
To assess which structural ensemble had the best overall conformations for in silico docking, we used 
the Schrödinger Glide [69] utility to dock the 27 ligands from the aforementioned small molecule set 
against our five structural ensembles, and then performed a comparative analysis of the resulting docking 
score distributions (Figure 5). In general, simulations with a greater degree of enhanced sampling tended 
towards better docking scores. Interestingly, the structural ensemble taken from the apo-Bcl-xL cosolvent 
aMD simulation repeatedly achieved better docking scores than any of the other ensembles—including 
the experimental structures—for virtually the entire ligand set. In fact, the median Glide docking score 
for the cosolvent aMD ensemble was lower than the median docking score for the crystal structure 
ensemble for all 27 members of our small molecule set, and the minimum score from the cosolvent aMD 
set was better than the minimum score for the crystal structures for 25 out of the 27 ligands. Of the two 
exceptions, one of these is the small molecule inhibitor identified by Lessene et al. [68]. Not surprisingly, 
we found that the members of the experimental structure ensemble that scored better than the cosolvent 
aMD were the structures from the Lessene hit co-complex itself (PDB codes: 3ZK6, 3ZLN, 3ZLO, 
3ZLR). The other exception was the natural compound chelerythrine, which docked best against the 
crystal structure for PUMA-bound Bcl-xL (PDB code: 2M04). 
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Figure 4. Chemical structures of 27 known inhibitors and two decoy compounds (Etoposide 
and Nutlin-3) selected for docking simulations. Numbers in parentheses are the molecular 
weights for each compound. 
We found, furthermore, that the average interquartile range of docking scores for the cosolvent aMD 
cluster representatives (1.74 kcal/mol) was larger than that for the experimental structure set (1.45 kcal/mol), 
whereas the average interquartile range of docking scores for the smaller ensembles was significantly 
reduced (pure water cMD: 0.52 kcal/mol; pure water aMD: 1.10 kcal/mol; cosolvent cMD: 0.68 kcal/mol). 
This observation, along with our analysis of the ligand-specific median and minimum ensemble docking 
scores, provides evidence that cosolvent aMD simulations can be used to generate a structural ensemble 
with characteristics similar to a large set of experimentally determined structures, as far as docking-related 
properties are concerned. 
The encouraging results of our docking simulations using the set of 27 known inhibitors motivated 
us to investigate the extent of general promiscuity of the binding site by screening against additional 
decoy compounds. We specifically included two non-binding compounds, etoposide and nutlin-3, used 
by Wan et al. [67], in addition to 145 fragment molecules provided by Dr. Isabelle Krimm—none of 
which were reported to bind Bcl-xL based on NMR fragment screening experiments [70]. Docking scores 
of these decoy molecules to our five structural ensembles exhibited similar trends to those of known 
inhibitors, i.e., the cosolvent aMD simulations gave better or comparable scores than those from the 
experimental Bcl-xL structures (Figure 5 and Figure S1). Many of the decoy compounds also gave a 
higher score value (weaker affinities) than known inhibitors of similar molecular weights (etoposide and 
nutlin-3 vs. gossypol and BH3I_2 in Figure 5). This reaffirmed the structural adaptability of the cosolvent 
aMD conformations in binding to small molecule ligands. Although we expect there would be hit 
enrichment using the cosolvent aMD Bcl-xL conformations in a larger scale in silico virtual screen, 
follow-up docking studies would have to be used to assess the overall suitability of these conformations 
for identifying useful hits. Future work will entail a detailed investigation of the effects of docking engine 
and scoring function choice on enrichment for known inhibitors. 
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Figure 5. A set of 27 known Bcl-xL inhibitors and two decoy compounds were docked 
against the simulated and experimental structure ensembles. The distributions of docking 
scores for each ligand (individual panels) from each ensemble are shown as box-and-whisker 
plots with outliers as black dots. Docking with the cosolvent aMD (blue)-derived conformations 
yielded the best overall scores. The horizontal black line in each panel denotes the score 
achieved by docking against the single X-ray apo structure from which simulations were 
initiated (see Experimental Section for details). 
3.5. Comparison of the Experimental and MD Generated Binding Site Conformations Using  
Grid-Based Hotspot Mapping and Sitemap Analysis 
To visualize and differentiate between the binding site conformations of different ensembles of Bcl-xL 
conformations in our docking evaluation, we implemented a grid-based hotspot mapping analysis. This 
method assesses the preferences of probe atoms positioned at uniformly-spaced grid points in the binding 
site of a protein conformation, based on scores calculated from the knowledge-based scoring function 
M-Score [56]. The higher the scores, the more favorable the interaction is between the protein and the 
probe at the specified position. Probe atoms at grid points with scores satisfying pre-defined criteria were 
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classified as hotspot grid points (see Experimental Section). Because the BH3 peptide binds to the  
BH3-domain binding-site of Bcl-xL primarily via hydrophobic interactions, an atom with the C.3 
(saturated carbon) type was used as the probe atom. To focus on the most important regions of the 
binding site, we selected hotspot grid points with scores lower than the fourth quantile of all hotspot 
scores in each ensemble of Bcl-xL conformations. The four consensus sites (h1–h4)—derived from the 
interacting hydrophobic residues of the BH3 peptide—were used as location references in the binding 
site (Figure 6A). Mapping of hotspot grid points obtained from all experimental Bcl-xL structures 
showed that in the apo state, the h3 and h4 sites are exposed and preformed, whereas the h2 and h1 sites 
are semi-exposed or completely buried. Conformational flexibility of the α3 and α4 helices facilitates 
binding site remodeling at the h1 and h2 sites for Bcl-xL, allowing it to bind to different ligands. The 
analysis also mapped a large cluster of hotspot grid points at a site below h3 that was recently shown to 
interact with the p53 DNA-binding domain in a Bcl-xL and p53 crystal structure complex [71]. In the 
ensembles of cMD and aMD conformations, the h4 site was more likely to be characterized as a hotspot 
while the pockets at the h1 and h2 sites were not well formed or buried. In contrast, hotspot maps for the 
ensemble of cosolvent MD generated conformations showed that a deeper pocket at the h2 site was 
induced. In summary, the analysis indicated that ligand-induced binding pockets at the h1 and h2 sites 
were not well represented by either cMD or aMD sampling in aqueous conditions, but were partly captured 
in the cosolvent MD simulation. 
 
Figure 6. Grid-based hotspot mapping of (A) 72 experimental Bcl-xL structures and 
representative conformations selected by hierarchical clustering using the trajectories of  
(B) cMD; (C) aMD; (D) cosolvent MD; or (E–H) cosolvent aMD simulations, starting from 
the apo-Bcl-xL structure (PDB ID: 1MAZ). The representative conformations selected in (E–G) 
are the cluster groups with the most (E) to the least (G) number of members. Grid points 
showing up more than twice in (E–G) are shown as the mesh shape and orange points in 
(H). Pockets that interact with four key hydrophobic residues from the BH3 peptide—such 
as that in the Bad protein—were shown in mesh envelopes and labeled as h1–h4 in (A). The 
color of the hotspot grid points in (A–G) from blue to red correspond to high or low score 
values as assessed by the M-Score function. The transparent surface of the apo-Bcl-xL structure 
was used as a reference to illustrate buried pockets identified in other Bcl-xL conformations. 
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Next, we analyzed the binding site conformations from the ensemble of cosolvent aMD structures, 
further dividing the set into three subgroups because of their broader conformational diversity (Figure 3). 
Based on the number of trajectory frames from each designated cluster (which ranged from 49 to 1), the 
subgroups were denoted as high-, middle-, or low-population clusters—resulting in three groups containing 
22, 20, and 22 conformations, respectively. In addition to the pockets discussed previously (Figure 6B–D), 
several other hydrophobic binding pockets were identified. They include a location buried in apo-Bcl-xL at 
the h1 site and another more deeply penetrating location close to the h2 site (blue circle in Figure 6E–G). 
The h4 site was clearly a well-defined pocket in all 64 conformations shown in Figure 6E–G. In Figure 
6H, we further selected the hotspot grid points appearing either two or three times in Figure 6E–G to 
highlight the recurrent hotspot grid points in the 64 conformations. Most of them fell into the mesh 
shapes representing hydrophobic residues of the BH3 peptide (see Figure 6A). These results suggest that 
the ligand-induced binding pockets at the h1 and h2 sites can be easily identified from the 64 
conformations obtained from the cosolvent aMD simulation. 
 
Figure 7. Sitemap analysis of the BH3-domain binding site in the ensemble of Bcl-xL 
conformations obtained from cMD, aMD low boost (aMD), cosolvent, cosolvent low boost 
aMD, and the experimental structures. The horizontal black line in each panel denotes the 
values calculated from the single X-ray apo Bcl-xL structure. 
Apart from our novel grid-based hotspot mapping analysis, we also used the Schrödinger Sitemap [55] 
utility to further analyze the Bcl-xL conformations. Sitemap has previously been applied to analyze 
protein-ligand co-crystal structures with known ligand binding affinities to provide a metric for assessing 
binding site druggability [55]. Based on previous studies, binding sites with Dscore values < 0.83 were 
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considered undruggable or very challenging. Our Sitemap analysis on the BH3-domain binding sites in 
72 Bcl-xL crystal structures gave an average Dscore value of 0.91, suggesting that it is a moderately 
challenging binding site (Figure 7). Of all five ensembles, the cosolvent aMD simulation gave the highest 
maximum Dscore value (1.43, compared to 1.06 for pure water cMD, 0.87 for pure water aMD, 1.26 for 
cosolvent cMD, and 1.18 for the experimental structures). A similar trend was found for the Sitescore 
values, which are known to be more useful for identifying binding sites in an overall protein structure. 
The sizes of the binding sites from the cosolvent aMD-generated conformations were also larger but 
more enclosed than those of the crystal structures. In addition, the exposure and enclosure of the binding 
sites in the cosolvent aMD conformations are closer to the values of the submicromolar sites (average 
exposure/enclosure = 0.52/0.76) analyzed previously by Halgren [55]. We conclude that the quantitative 
analysis from Sitemap is consistent with the results of our novel grid-based hotspot mapping analysis 
(Figure 6E–H). 
4. Conclusions 
Proteins involved in protein–protein interactions have traditionally been considered difficult targets 
for small molecule inhibitor development. A recent review by Arkin et al. summarized progress in the 
field, including several inhibitors that are in clinical trials—providing strong evidence that this difficult 
class of protein targets is still tractable for therapeutic development [20]. The anti-apoptotic members of 
the Bcl-2 family, such as Bcl-xL, are one relatively successful example. The challenge in developing 
inhibitors targeting Bcl-xL has been attributed to the long hydrophobic BH3 domain binding groove, 
flanked by two inherently flexible helices forming the binding pocket—as described in this study. 
In this work, we have combined the recently developed accelerated MD method (which enhances 
sampling of binding site conformations) with the cosolvent MD simulation method, which allows small 
organic cosolvent molecules to probe and reshape the Bcl-xL binding site. Principal component analysis 
confirmed that the approach samples a wide range of the crystal structure conformational space, and that 
our simulation of the Bad-bound Bcl-xL conformation in water induced relaxation to the apo state. The 
diverse Bcl-xL conformations obtained from the cosolvent aMD simulation were further analyzed via 
hierarchical clustering to select representative conformations. Using 27 known inhibitors ranging from 
fragment molecules to a large macrocyclic compound (Kendomycin)—with molecular weights from 117 
to 535—in our in silico screening evaluation, we have shown that the ensemble of Bcl-xL conformations 
obtained from the cosolvent aMD simulation gave better median scores than ensembles of Bcl-xL 
conformations obtained using different simulation protocols or from experimental structures. These 
more favorable docking scores would suggest a better complementary fit between the small molecule 
inhibitors and the Bcl-xL conformations. 
Analyses of the Bcl-xL conformations using our grid-based mapping method and the Sitemap 
program revealed that buried binding pockets at two locations (i.e., h1 and h2 sites) can be well-characterized 
in the ensemble of Bcl-xL conformations from the cosolvent aMD simulations, but not for the conformations 
obtained from cMD and aMD simulations in aqueous conditions. These two buried pockets can be 
readily identified in several ligand-bound Bcl-xL experimental structures. An important point regarding 
our ensemble of Bcl-xL conformations obtained from the cosolvent aMD simulations is that we used the 
apo form of Bcl-xL as the starting conformation. In relation to our previous report that cosolvent 
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molecules can promote and stabilize Bcl-xL conformations resembling ligand-bound structures, we 
found that the cosolvent aMD simulation also allowed greater conformational sampling of these types 
of conformations than a conventional cosolvent MD simulation. Thus, the cosolvent aMD method is an 
attractive sampling approach for enrichment of binding site conformations that are suitable for an in 
silico screening campaign using small molecules. We plan to carry out a detailed assessment of the Bcl-xL 
conformations obtained from our cosolvent aMD simulations, with the ultimate goal of achieving hit 
enrichment in a larger in silico screening campaign. This analysis will also include a comparison of 
different docking engines, the inclusion of a larger decoy compound dataset [72], and the exploration of 
experimentally validated inhibitors of Bcl-xL. 
In summary, we conclude that this approach could be useful for investigating other targets with large 
protein–protein binding interfaces, particularly in cases where only an apo form crystal structure is 
available. Although our study was aided by the relative abundance of high-resolution Bcl-xL crystal 
structures, it stands as proof-of-concept for the overall approach, and certainly the most promising application 
of cosolvent aMD simulations would be for targets with less accumulated structural data. Nevertheless, a 
recent study addressing the validity of using long-timescale molecular dynamics simulations to refine protein 
homology models suggested there might be substantial limitations in the use of current force field parameters 
for characterizing conformations substantially away from native states in other protein systems [73]. We are 
currently investigating the applicability of our method to other protein targets outside the Bcl-2 family. 
These studies will provide more insight on the ways in which our approach can be generalized to help 
identify inhibitors for other important but challenging protein-protein interaction targets. 
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